Wuxi Biologics (Cayman) Inc. has issued a positive profit alert for the first half of 2025, indicating a favorable financial outlook for the period ending June 30, 2025. The announcement, based on a preliminary assessment of the unaudited consolidated management accounts, suggests that the company is poised to report strong interim results, which are expected to be officially published on August 19, 2025. The company attributes its positive performance to several factors, including an expanded range of services for the biologics industry, growth in research services revenue, enhanced utilization of manufacturing capacities, and efficiency improvements from digitalization initiatives. Additionally, investment gains from the company's portfolio have also contributed to the anticipated profit increase. However, the results are still subject to finalization and potential adjustments, and shareholders are advised to exercise caution when dealing with the company's shares.